Company registration number 08008790 (England and Wales)
ATHERSTONE PHARMA LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
ATHERSTONE PHARMA LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 4
ATHERSTONE PHARMA LIMITED
BALANCE SHEET
AS AT 31 MARCH 2025
31 March 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
4
-
0
1,071
Current assets
Stocks
64,685
70,692
Debtors
5
533,017
219,664
Cash at bank and in hand
167,532
15,230
765,234
305,586
Creditors: amounts falling due within one year
6
(860,434)
(411,735)
Net current liabilities
(95,200)
(106,149)
Total assets less current liabilities
(95,200)
(105,078)
Provisions for liabilities
20,000
47,886
Net liabilities
(75,200)
(57,192)
Capital and reserves
Called up share capital
7
7
Share premium account
98,999
98,999
Capital redemption reserve
1
1
Other reserves
83,994
-
0
Profit and loss reserves
(258,201)
(156,199)
Total equity
(75,200)
(57,192)

For the financial year ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 22 December 2025 and are signed on its behalf by:
Kishan Mehta
Director
Company registration number 08008790 (England and Wales)
ATHERSTONE PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 2 -
1
Accounting policies
Company information

Atherstone Pharma Limited is a private company limited by shares incorporated in England and Wales. The registered office is 1 Ratcliffe Road, Atherstone, Warwickshire, CV9 1EU.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
20% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

1.6
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

ATHERSTONE PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 3 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.7
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.8
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
28
29
3
Taxation
2025
2024
£
£
Deferred tax
Origination and reversal of timing differences
27,886
(22,629)
ATHERSTONE PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 4 -
4
Tangible fixed assets
Fixtures and fittings
£
Cost
At 1 April 2024 and 31 March 2025
15,545
Depreciation and impairment
At 1 April 2024
14,984
Depreciation charged in the year
561
At 31 March 2025
15,545
Carrying amount
At 31 March 2025
-
0
At 31 March 2024
1,071
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
411,147
192,691
Other debtors
121,870
26,973
533,017
219,664
6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
305,901
327,655
Taxation and social security
9,663
8,905
Other creditors
544,870
75,175
860,434
411,735
7
Ultimate Controlling Party

The company is controlled by Atherstone Medical Ltd.

2025-03-312024-04-01falsefalsefalse22 December 2025CCH SoftwareCCH Accounts Production 2025.200No description of principal activityKishan MehtaBhapinder BainsJeetender Sahota080087902024-04-012025-03-31080087902025-03-31080087902024-03-3108008790core:FurnitureFittings2025-03-3108008790core:FurnitureFittings2024-03-3108008790core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-3108008790core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3108008790core:ShareCapital2025-03-3108008790core:ShareCapital2024-03-3108008790core:SharePremium2025-03-3108008790core:SharePremium2024-03-3108008790core:CapitalRedemptionReserve2025-03-3108008790core:CapitalRedemptionReserve2024-03-3108008790core:OtherMiscellaneousReserve2025-03-3108008790core:OtherMiscellaneousReserve2024-03-3108008790core:RetainedEarningsAccumulatedLosses2025-03-3108008790core:RetainedEarningsAccumulatedLosses2024-03-3108008790bus:Director12024-04-012025-03-3108008790core:FurnitureFittings2024-04-012025-03-31080087902023-04-012024-03-3108008790core:FurnitureFittings2024-03-3108008790core:CurrentFinancialInstruments2025-03-3108008790core:CurrentFinancialInstruments2024-03-3108008790core:WithinOneYear2025-03-3108008790core:WithinOneYear2024-03-3108008790bus:PrivateLimitedCompanyLtd2024-04-012025-03-3108008790bus:FRS1022024-04-012025-03-3108008790bus:AuditExemptWithAccountantsReport2024-04-012025-03-3108008790bus:Director22024-04-012025-03-3108008790bus:Director32024-04-012025-03-3108008790bus:SmallCompaniesRegimeForAccounts2024-04-012025-03-3108008790bus:FullAccounts2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP